Savolitinib

Savolitinib is an oral, selective MET inhibitor co-developed by AstraZeneca and HUTCHMED, already approved in China as Orpathys for MET exon 14-altered non-small cell lung cancer. The bigger near-term commercial story is its expansion into EGFR-mutant lung cancer, where the SACHI Phase 3 trial (savolitinib plus osimertinib versus chemotherapy in patients who progressed on first-line EGFR TKI with MET amplification) reported positive interim PFS data in The Lancet in January 2026 - investigator-assessed median PFS 8.2 months versus 4.5 months for chemotherapy, hazard ratio 0.34 (95% CI 0.23-0.49, p<0.0001) [1]. A separate Phase 3 in MET-driven papillary renal cell carcinoma (NCT03091192) [2] anchors the original kidney cancer indication. For AstraZeneca - a company with $54.1B in FY2024 total revenue [9] - savolitinib is a niche but strategically important tuck-in: it props up the Tagrisso (osimertinib) franchise by giving doctors a paired drug to use when osimertinib stops working because the tumor has rewired through MET.

Savolitinib is not a novel compound globally - it's approved in China (Orpathys, June 2021) for MET exon 14 skipping NSCLC [3]. What's investigational is everything else: papillary RCC (Phase 3, SAVOIR-derived NCT03091192) [2], EGFR-mutant MET-amplified NSCLC after first-line EGFR TKI (SACHI, NCT05261399) [4], and first-line EGFR/MET dual blockade (FLOWERS Phase 2) [5]. The most actionable readout is SACHI - the interim Phase 3 analysis published in The Lancet in January 2026 showed investigator-assessed median PFS 8.2 months (95% CI 6.9-11.2) for savolitinib+osimertinib versus 4.5 months (95% CI 3.0-5.4) for platinum doublet chemotherapy, HR 0.34 (95% CI 0.23-0.49, p<0.0001); blinded independent central review was concordant at 7.2 vs 4.2 months, HR 0.40 [1]. Overall survival data were immature at the interim and not reported as a co-primary, which is a known FDA scrutiny point for any subsequent US filing. AstraZeneca has not publicly disclosed an FDA breakthrough or accelerated approval designation for the EGFR-mutant indication as of early 2026. A US filing will almost certainly require a companion diagnostic to define the MET-amplified/overexpressed eligible population - the specific cutoff (FISH copy number, NGS, or IHC) is not yet locked and will materially shape addressable market. The papillary RCC program is smaller (n=60, NCT03091192) and slower; final data from the CALYPSO combination study with durvalumab in metastatic papillary RCC was reported in J Clin Oncol in 2026, but the savolitinib monotherapy Phase 3 readout in PRCC remains the gating event for that indication [6].

MET is a receptor on the surface of cells that, when its partner protein HGF (hepatocyte growth factor) binds to it, tells the cell to grow, move, and survive. It's a normal wound-healing signal. In cancer, MET gets stuck in the 'on' position - sometimes because of a specific genetic glitch called MET exon 14 skipping (the cell loses the brake that normally turns MET off), sometimes because the cancer has too many copies of the MET gene (amplification), and sometimes because EGFR-mutant lung cancers under pressure from osimertinib find MET as an escape route. Savolitinib is a small pill that fits into the ATP-binding pocket of the MET protein and stops it from firing [7]. The mechanism is genetically validated - MET exon 14 mutations and MET amplification are clear oncogenic drivers, and the FDA has already approved two competing small-molecule MET inhibitors (capmatinib/Tabrecta from Novartis, tepotinib/Tepmetko from Merck KGaA) on the basis of single-arm response data in MET exon 14 NSCLC. So the question isn't whether blocking MET works - it does - but whether savolitinib's selectivity advantage and the AstraZeneca combination strategy with osimertinib carve out a defensible commercial niche.

Two trials matter most. SACHI (NCT05261399) is a randomized, open-label Phase 3, n≈211 in the interim analysis (planned ~345), enrolling Chinese patients with EGFR-mutant NSCLC and MET amplification (FISH-confirmed) who progressed on first-line EGFR TKI [4]. Patients get savolitinib + osimertinib versus platinum doublet chemotherapy. Primary endpoint is investigator-assessed PFS. The interim analysis published in The Lancet (PMID 41544643) reported investigator-assessed median PFS 8.2 vs 4.5 months, HR 0.34 (95% CI 0.23-0.49, p<0.0001), and IRC-assessed median PFS 7.2 vs 4.2 months, HR 0.40 (95% CI 0.28-0.59, p<0.0001) [1]. Overall survival was immature. The design is clean: the comparator is real-world standard of care (chemo), the biomarker (MET amplification) is enrichment for the mechanism, and the population is well-defined - but the China-only enrollment will be a question for FDA review. The papillary RCC trial (NCT03091192) is smaller (n=60), randomized against sunitinib, with PFS by blinded independent central review as the primary endpoint [2]. The original SAVOIR Phase 3 in PRCC stopped early in 2020 after external sunitinib data in MET-driven disease showed better-than-expected real-world PFS, undermining the trial's powering assumptions [10]; the current NCT03091192 study is the salvage effort. The FLOWERS Phase 2 (first-line, n=44) showed an ORR (objective response rate) advantage for the savolitinib+osimertinib combination over osimertinib alone, but it's hypothesis-generating, not registrational [5].

Our model estimates a 21% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by its light or open-label blinding and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results and smaller-than-typical enrollment for this phase. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Three concrete risks. First, the SACHI control arm is platinum doublet chemotherapy, not a competing MET-directed regimen. The most direct competitor is amivantamab+lazertinib (J&J), which is FDA-approved in the first-line EGFRm setting (MARIPOSA, August 2024) [8]; in the post-osimertinib setting amivantamab has Phase 1b CHRYSALIS-2 data (ORR ~35% in cohort A) but is not yet approved there [11]. So today the competitive picture is approved first-line bispecific antibody combination (IV+oral) versus an oral TKI stack (savolitinib+osimertinib) seeking second-line approval - a real modality difference that affects payer coverage, infusion-center logistics, and physician workflow. Second, savolitinib has a known liver toxicity signal - Grade 3+ ALT/AST elevations have been reported across multiple trials, and the Chinese label includes hepatotoxicity warnings. In combination with osimertinib (which has hepatic and cardiac signals of its own), the long-duration safety profile is a real concern. Third, the MET biomarker question is unsettled - what level of amplification or overexpression actually predicts response? FDA approval will require a companion diagnostic, and a stringent cutoff (e.g., high-level FISH amplification only) could shrink the addressable population. Commercial risk: even if approved, this is a niche second-line indication (estimated 15-25% of osimertinib failures have MET-driven resistance), so peak sales likely sit in the $500M-$1B range globally, not blockbuster territory. IP tail: savolitinib composition-of-matter protection is in the mid-2030s, so the post-launch commercial runway is tight but not immediate.

Worth watching, leaning toward signal. The SACHI positive interim in The Lancet - HR 0.34, median PFS nearly doubled - is the most important data point this program has ever produced [1]. The next concrete catalyst is the AstraZeneca regulatory filing in the US/EU for the post-EGFR-TKI MET-amplified indication, with the open question of whether FDA will accept the China-only dataset or require a bridging study. Expect filing commentary on AstraZeneca's Q2 and Q3 2026 earnings calls, along with companion diagnostic partner disclosure. The competitive question is the one to track: how does savolitinib+osimertinib position against amivantamab+lazertinib if the latter wins a post-osimertinib label expansion from CHRYSALIS-2 / MARIPOSA-2-style data. AZ has the distribution advantage because it already owns the osimertinib base - oncologists comfortable with Tagrisso will find it easier to add an AZ partner oral than switch to a J&J IV bispecific. For HUTCHMED (~$300M market cap range), savolitinib milestone and royalty payments from AstraZeneca on ex-China sales are material to the P&L. The papillary RCC indication is noise - small market, slow trial, and the field has moved on.